- What changed in KROS news today?
- Keros Therapeutics swings to Q3 net income of $14.15 million: Keros Therapeutics reported third-quarter 2026 net income of $14.15 million, primarily due to revenue recognized under its Takeda license agreement. Revenue more than doubled year over year to $40.01 million, and the company had $259.46 million in cash and cash equivalents at September 30.
- Does Rallies summarize KROS news?
- Yes. Rallies summarizes KROS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is KROS research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for KROS. It does not provide personalized investment advice.
